What are the odds of getting melanoma from regular unprotected sun exposure?
Evidence quality 4.75/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, subgroup
1 in 29
3.4% lifetime chance
Most people underestimate this.
range 1 in 40 to 1 in 22
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Most people know that sun exposure causes skin cancer in a vague, background-knowledge sort of way, yet UV protection remains inconsistent: fewer than half of US adults report regular sunscreen use, and tanning beds still attract millions of users per year. Melanoma is the fifth most common cancer in the United States, but its lethality relative to its incidence does not register the way lung or pancreatic cancer does. The result is a risk that most people file as "probably fine if I'm careful" rather than one they actively calibrate against.
Rough estimate: 50% of US adults are very or somewhat worried about getting cancer (Gallup, all sites); melanoma-specific worry is lower and inconsistent with actual UV behavior
Source: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
Actual
~1 in 29 lifetime (non-Hispanic white US men, diagnosis)
non-Hispanic white US adults
Show derivation
Uses the American Cancer Society direct lifetime probability from SEER 2020-2022 data: 3.5% (1 in 29) for non-Hispanic white men and 2.5% (1 in 40) for non-Hispanic white women. The headline figure of 0.034 is the sex-averaged midpoint weighted toward the higher male rate, reflecting the population-level lifetime diagnosis probability for fair-skinned US adults with typical (i.e., inconsistent) UV protection behavior. This is a diagnosis probability, not a mortality probability — the 5-year relative survival for melanoma is ~95% overall and ~99% for localized disease. Mortality lifetime risk is much lower: ~0.4% for white men (1 in 269), ~0.2% for white women (1 in 496). The ~86% UV-attributable fraction (per the American Academy of Dermatology and WHO) means the vast majority of this risk is behavior-modifiable.
Caveats: This entry reports diagnosis probability, not mortality. Melanoma caught early (…
This entry reports diagnosis probability, not mortality. Melanoma caught early (localized stage) has a 99% five-year survival rate; the lifetime mortality risk for white US adults is roughly an order of magnitude lower than the diagnosis risk (~0.4% for men, ~0.2% for women). The "underrated" framing refers specifically to the gap between the high population-level incidence and the inconsistent UV protection behavior: melanoma is the 5th most common US cancer, yet regular sunscreen use remains a minority behavior. The ~86% UV-attributable fraction (widely cited by WHO, AAD, and others) makes melanoma one of the most preventable common cancers, yet prevention behavior does not match. The Green et al. RCT confidence intervals are wide (the overall HR 0.50 had p=.051), so the "50% reduction" figure should be read as the best available RCT point estimate rather than a precise effect size. Fair-skinned subgroup scoping means the headline number does not apply to Black, Hispanic, or Asian Americans, for whom melanoma risk is dramatically lower.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Non-Hispanic white US men | 1 in 29 |
ACS direct lifetime probability from SEER 2020-2022; 1 in 29 |
| Non-Hispanic white US women | 1 in 40 |
ACS direct lifetime probability from SEER 2020-2022; 1 in 40 |
| US overall (all races) | 1 in 45 |
SEER all-race figure; ~2.2% lifetime diagnosis probability |
| Hispanic US adults | 1 in 200 |
ACS estimate; 1 in 200 |
| Black US adults | 1 in 1,000 |
ACS estimate; 1 in 1,000 — incidence ~30-40x lower than non-Hispanic white |
| Australia (fair-skinned) | 1 in 20 |
Australia has the highest melanoma incidence rate globally; estimated ~1 in 20 lifetime for fair-skinned Australians |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Charred meat & cancer
How much does eating charred or well-done grilled meat actually raise your cancer risk?
Low-fiber CRC risk
What are the odds of getting colorectal cancer from not eating enough fiber?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Fair-skinned Americans face a lifetime melanoma diagnosis probability of roughly 1 in 29 for men and 1 in 40 for women, according to ACS lifetime tables built on SEER 2020-2022 data. That puts melanoma in the same order of magnitude as the lifetime risk of dying from lung cancer — except melanoma is far more survivable (99% five-year survival when caught localized) and far more preventable. An estimated 86% of melanomas are attributable to UV exposure, and the only randomized trial ever conducted on sunscreen and melanoma — Green et al.’s Nambour RCT in Queensland — found that daily sunscreen users developed half the melanomas of discretionary users over a decade of follow-up.
What makes melanoma underrated is not the absolute numbers but the behavioral gap. It is the fifth most common cancer in the United States, with an estimated 234,680 new cases projected for 2026, yet regular sunscreen use remains a minority habit. Five or more blistering sunburns between ages 15 and 20 raise lifetime melanoma risk by 80%, and indoor tanning before age 35 raises it by 59-75% depending on the meta-analysis. These are large, well-documented effect sizes attached to common behaviors that many people treat as cosmetically optional rather than oncologically relevant.
The headline number is scoped to non-Hispanic white adults for a reason: race is the single largest non-modifiable axis of variation. Black Americans face a melanoma risk roughly 30 to 40 times lower than white Americans (about 1 in 1,000 lifetime vs 1 in 33 overall for white adults). Within the fair-skinned subgroup, the personal spread is still large — Fitzpatrick type I-II skin, high mole count, family history, and adolescent sunburn history can each roughly double the baseline, while consistent broad-spectrum sunscreen use can roughly halve it. Australia, with the world’s highest melanoma incidence, illustrates the ceiling: fair-skinned Australians face roughly a 1-in-20 lifetime risk.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] American Cancer Society — Lifetime Probability of Developing or Dying From Cancer
Lifetime Probability of Developing or Dying From CancerSee all 3 Likelier entries citing this source →
- Statistic
Melanoma of the skin: men 3.5% (1 in 29) risk of developing, 0.4% (1 in 269) risk of dying; women 2.5% (1 in 40) risk of developing, 0.2% (1 in 496) risk of dying — figures are for non-Hispanic White people- Excerpt
“"Melanoma of the skin: 3.5% risk of developing (1 in 29), 0.4% risk of dying from (1 in 269) [men]. Melanoma of the skin: 2.5% risk of developing (1 in 40), 0.2% risk of dying from (1 in 496) [women]. [...] The risk numbers for melanoma are for non-Hispanic White people." ”
- Source data from
- 2025-01-30
- Accessed
- 2026-04-11 · archived copy
- Calculation
- ACS uses SEER mortality and incidence data (2020-2022) to compute direct lifetime probabilities from a life-table conditional on birth. The 3.5% male and 2.5% female figures are the gold standard for US non-Hispanic white lifetime melanoma diagnosis risk. Sex-averaged midpoint: (0.035 + 0.025) / 2 = 0.030; weighted slightly toward the male rate (higher incidence, larger share of melanoma burden) gives ~0.034 as the headline. Uncertainty band 0.025-0.045 spans the female-only to the upper bound for high-UV-exposure male subgroups.
- Independence
- ACS lifetime probability tables are built directly on SEER 2020-2022 incidence/mortality data and life tables from the same NCHS pipeline referenced by the SEER Stat Facts source below. Treat ACS and SEER as one analytical pipeline on a shared upstream dataset; the AAD and Green (Nambour RCT) sources provide the genuine independent verification.
-
[2] National Cancer Institute / SEER Program — Cancer Stat Facts: Melanoma of the Skin
Cancer Stat Facts: Melanoma of the Skin- Statistic
Approximately 2.2% of men and women will be diagnosed with melanoma at some point during their lifetime; non-Hispanic white males 39.7 per 100,000/year, non-Hispanic white females 26.8 per 100,000/year; 5-year relative survival 94.7%- Excerpt
“"Approximately 2.2 percent of men and women will be diagnosed with melanoma of the skin at some point during their lifetime." ”
- Source data from
- 2024-01-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- SEER's 2.2% overall figure covers all races/ethnicities. Non-Hispanic white incidence rates (39.7 M, 26.8 F per 100,000/year) are roughly 30-40x the rates for Black Americans (1.0 M, 0.9 F), confirming the enormous racial disparity that justifies scoping this entry to fair-skinned adults. The 94.7% 5-year survival rate underscores that melanoma diagnosis risk far exceeds mortality risk.
- Independence
- SEER is the upstream data source for the ACS lifetime probability calculations in source 1. Treat as the same pipeline for incidence/mortality figures; included here for the race-stratified incidence rates and overall population figure.
-
[3] Journal of Clinical Oncology / Green AC, Williams GM, Logan V, Strutton GM — Reduced melanoma after regular sunscreen use: randomized trial follow-up
Reduced melanoma after regular sunscreen use: randomized trial follow-up- Statistic
Daily sunscreen users had half the melanoma incidence of discretionary users (HR 0.50, 95% CI 0.24-1.02); invasive melanoma reduction was 73% (HR 0.27, 95% CI 0.08-0.97)- Excerpt
“"11 new primary melanomas had been identified in the daily sunscreen group, and 22 had been identified in the discretionary group (hazard ratio [HR], 0.50; 95% CI, 0.24 to 1.02; P = .051). The reduction in invasive melanomas was substantial (n = 3 in active v 11 in control group; HR, 0.27; 95% CI, 0.08 to 0.97)." ”
- Source data from
- 2011-01-20
- Accessed
- 2026-04-11 · archived copy
- Calculation
- The Nambour RCT (Queensland, Australia; 1,621 participants; 1992-2006 follow-up) is the only large-scale randomized trial of sunscreen for melanoma prevention. The overall HR of 0.50 (borderline significance at p=.051) and the invasive-melanoma HR of 0.27 (significant) anchor the "~50% melanoma reduction with regular sunscreen" claim used in personal_factor_multipliers. The wide confidence intervals reflect the relatively small number of melanoma events (33 total) over the 10-year follow-up.
- Independence
- Fully independent of SEER/ACS pipeline — Australian population-based RCT with its own endpoint ascertainment.
-
[4] American Academy of Dermatology — Skin cancer statistics
Skin cancer statistics- Statistic
1 in 28 men and 1 in 39 women lifetime melanoma risk; 5+ blistering sunburns age 15-20 increases melanoma risk by 80%; indoor tanning before 30 increases melanoma risk 6x for women- Excerpt
“"It is estimated that melanoma will affect 1 in 28 men and 1 in 39 women in their lifetime. [...] Experiencing five or more blistering sunburns between ages 15 and 20 increases one's melanoma risk by 80% and nonmelanoma skin cancer risk by 68%." ”
- Source data from
- 2025-01-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- AAD figures (1 in 28 M, 1 in 39 F) are marginally different from ACS (1 in 29 M, 1 in 40 F) due to different data vintage and rounding; both are within expected variation. The 80% sunburn multiplier (5+ blistering sunburns age 15-20) and the indoor tanning risk figures are used in personal_factor_multipliers.
- Independence
- AAD compiles statistics from multiple sources including SEER, ACS, and independent dermatology literature. The sunburn and tanning bed figures derive from separate epidemiological studies (Lew et al., Lazovich et al.) and are independently sourced from the SEER lifetime probability.